Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Participants needed: 412
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: AB ScienceUpdated: Oct 3, 2025Locations: 1
Eligibility criteria

The patient must have been diagnosed with clinically probable or definite ALS ba... [+6]

Patients should not have any significant neurological, psychiatric, systemic or... [+8]

Read more
Status: Not yet recruiting

Masitinib in Patients With Mild Alzheimer's Disease

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Participants needed: 600
Trial details
Phase: Phase 3Age: 50+Biological sex: AllType: InterventionalSponsor: AB ScienceUpdated: Oct 3, 2025Locations: 9
Eligibility criteria

Patient with clinical diagnosis of Alzheimer's disease based on criteria defined... [+7]

Patients with any other cause of dementia shown by MRI findings and neurological... [+3]

Read more
Status: Recruiting

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Participants needed: 78
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AB ScienceUpdated: Oct 2, 2025Locations: 10
Eligibility criteria

Patients with documented diagnosis of acute myeloid leukemia (AML) based on the... [+4]

Patients eligible to a standard of care [+17]

Read more
Status: Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Participants needed: 495
Trial details
Phase: Phase 3Age: 18-81Biological sex: AllType: InterventionalSponsor: AB ScienceUpdated: Sep 12, 2025Locations: 56
Eligibility criteria

Patients diagnosed with laboratory supported probable, clinically probable or de... [+5]

Patient with dementia or significant neurological, psychiatric, systemic or orga... [+2]

Read more